Mary Kay Koenig, MD
Neurology with Special Qualifications in Child Neurology · Houston, TXNPI 1881895993
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Novartis at 39.9% of the total. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $527.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$68K
- Jazz Pharmaceuticals Inc.$50K
- Immedica Pharma US, Inc.$20K
- Acadia Pharmaceuticals Inc$13K
- Greenwich Biosciences, Inc.$8K
- UCB SA$3K
- plus $8K from 20 others
Across 193 payments — averaging $5943.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Immedica Pharma US, Inc.$389K
- PTC Therapeutics, Inc.$360K
- Astellas Pharma Inc$208K
- Jazz Pharmaceuticals Inc.$138K
- Pfizer$42K
- Novartis$5K
- plus $5K from 1 others
What the payments were for
- Consulting fees$33,56720%
- Speaking & faculty fees$100,55459%
- Travel & lodging$28,70417%
- Food & beverage$7,9515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 102 | $68,176 |
| Jazz Pharmaceuticals Inc. | 87 | $50,399 |
| Immedica Pharma US, Inc. | 16 | $20,190 |
| Acadia Pharmaceuticals Inc | 15 | $12,661 |
| Greenwich Biosciences, Inc. | 21 | $8,371 |
| UCB SA | 3 | $3,200 |
| H. Lundbeck A S | 5 | $2,084 |
| PTC Therapeutics, Inc. | 2 | $2,030 |
| UCB, Inc. | 32 | $1,194 |
| Zogenix Inc. | 1 | $1,000 |
| Vertex | 1 | $517 |
| Biogen | 6 | $159 |
| Upsher-smith Laboratories LLC | 5 | $135 |
| Eisai Inc. | 6 | $128 |
| Sunovion Pharmaceuticals Inc. | 7 | $125 |
| Ultragenyx Pharmaceutical Inc. | 1 | $122 |
| Neurocrine Biosciences, Inc. | 3 | $81 |
| SK Life Science, Inc. | 2 | $53 |
| Pyros Pharmaceuticals, Inc. | 1 | $30 |
| Bioventus LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Aprecia Pharmaceuticals, LLC | 1 | $22 |
| Neurelis, Inc. | 1 | $19 |
| Livanova USA, Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 2 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$170,775 in reported general payments places this provider in the 95th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vigabatrin | 12 | $312,349 |
| TrileptalOxcarbazepine | 12 | $23,152 |
| Everolimus | 13 | $21,001 |
| LamictalLamotrigine | 12 | $9,137 |
| Oxcarbazepine | 18 | $3,839 |
| Clobazam | 34 | $3,099 |
| Levetiracetam | 54 | $3,049 |
| Carbamazepine ErCarbamazepine | 12 | $1,179 |
| Zonisamide | 12 | $376 |
| Guanfacine Hcl ErGuanfacine Hcl | 12 | $245 |
| Clonazepam | 14 | $97 |
| Sertraline Hcl | 31 | $47 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Houston
- Huda ZoghbiHouston$5.5M
- Shade MoodyHouston$194K
- Gretchen von AllmenHouston$31K
- Victoria HardwickHouston$10K
- Joshua RotenbergHouston$9K
- Mered ParnesHouston$5K
- Sarah WilsonHouston$5K
- Roy EltermanDallas$5.9M
- Diana CastroDenton$343K
- Michael PerryFort Worth$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.